NASDAQ:ETNB 89bio (ETNB) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free ETNB Stock Alerts $7.90 +0.12 (+1.54%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$7.64▼$8.0250-Day Range$7.78▼$11.6452-Week Range$6.57▼$22.93Volume984,707 shsAverage Volume713,998 shsMarket Capitalization$777.20 millionP/E RatioN/ADividend YieldN/APrice Target$28.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get 89bio alerts: Email Address 89bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside256.2% Upside$28.14 Price TargetShort InterestHealthy10.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.31Based on 4 Articles This WeekInsider TradingAcquiring Shares$20.72 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.42) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.17 out of 5 starsMedical Sector353rd out of 928 stocksPharmaceutical Preparations Industry161st out of 437 stocks 4.4 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst Coverage89bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 89bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.29% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in 89bio has recently decreased by 5.86%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 4.1 News and Social Media Coverage News Sentiment89bio has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 89bio this week, compared to 3 articles on an average week.Search Interest10 people have searched for ETNB on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows5 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,722,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.80% of the stock of 89bio is held by insiders.Read more about 89bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($2.42) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 89bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About 89bio Stock (NASDAQ:ETNB)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Read More ETNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETNB Stock News HeadlinesMay 23, 2024 | seekingalpha.com89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong BuyMay 22, 2024 | globenewswire.com89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver CongressMay 16, 2024 | markets.businessinsider.comBuy Rating for 89bio on Pegozafermin’s Promise in Advanced NASH TrialsMay 15, 2024 | morningstar.com89bio Inc Ordinary SharesMay 14, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on 89bio (ETNB)May 14, 2024 | globenewswire.com89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated CirrhosisMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Pegozafermin’s Clinical Advances and Market PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Promising Drug Candidate Progress and Strategic ReadinessMay 10, 2024 | finance.yahoo.com89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical TrialsMay 10, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2024 | msn.comETNB Stock Earnings: 89bio Misses EPS for Q1 2024May 9, 2024 | globenewswire.com89bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.com89bio to Participate in the BofA Securities 2024 Health Care ConferenceMay 2, 2024 | finance.yahoo.com89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASHMay 2, 2024 | globenewswire.com89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASHApril 24, 2024 | investing.comBofA raises 89bio to stock buy amid MASH outlookApril 22, 2024 | finance.yahoo.com89bio, Inc. (ETNB) Stock Historical Prices & Data - Yahoo FinanceApril 17, 2024 | globenewswire.com89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsApril 5, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2024 | finance.yahoo.com89bio Inc CEO Rohan Palekar Sells 52,718 SharesMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio’s Pegozafermin: A Promising NASH Treatment with Strong Regulatory EndorsementsMarch 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)March 27, 2024 | globenewswire.com89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated CirrhosisMarch 16, 2024 | finance.yahoo.comETNB Apr 2024 12.500 putMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)See More Headlines Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/02/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$28.14 High Stock Price Target$37.00 Low Stock Price Target$14.00 Potential Upside/Downside+256.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.76% Return on Assets-31.05% Debt Debt-to-Equity Ratio0.05 Current Ratio15.03 Quick Ratio15.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.19 per share Price / Book1.52Miscellaneous Outstanding Shares98,380,000Free Float95,629,000Market Cap$777.20 million OptionableOptionable Beta1.15 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Rohan Palekar (Age 58)CEO & Director Comp: $1.06MMr. Quoc Le-Nguyen (Age 56)Chief Technical Operations Officer Comp: $702.87kDr. Harry Mansbach M.D. (Age 59)Chief Medical Officer Comp: $732.87kMr. Ryan Stephen Martins (Age 45)Chief Financial Officer Mr. Shiva K. Natarajan CPA (Age 58)Senior Vice President of Finance & Principal Accounting Officer Ms. Annie J. Chang M.B.A.VP of Investor Relations & Corporate CommunicationsMs. Amanda KuriharaVice President of People & CultureMs. Melissa AbelSenior Vice President of Commercial StrategyMr. Paul ShinSenior Vice President of R&D OperationsMr. Michael BaldwinVP & Head of QualityMore ExecutivesKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTAlbireo PharmaNASDAQ:ALBOAkero TherapeuticsNASDAQ:AKROBiohavenNYSE:BHVNAmicus TherapeuticsNASDAQ:FOLDView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Bought 1,350,000 shares on 5/17/2024Ownership: 12.977%Comerica BankBought 15,070 shares on 5/17/2024Ownership: 0.174%Janus Henderson Group PLCBought 3,688,241 shares on 5/16/2024Ownership: 12.811%Redmile Group LLCBought 295,164 shares on 5/16/2024Ownership: 2.302%Bellevue Group AGSold 6,500 shares on 5/15/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions ETNB Stock Analysis - Frequently Asked Questions Should I buy or sell 89bio stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ETNB shares. View ETNB analyst ratings or view top-rated stocks. What is 89bio's stock price target for 2024? 7 equities research analysts have issued twelve-month price objectives for 89bio's shares. Their ETNB share price targets range from $14.00 to $37.00. On average, they predict the company's stock price to reach $28.14 in the next twelve months. This suggests a possible upside of 256.2% from the stock's current price. View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts. How have ETNB shares performed in 2024? 89bio's stock was trading at $11.17 at the beginning of the year. Since then, ETNB stock has decreased by 29.3% and is now trading at $7.90. View the best growth stocks for 2024 here. Are investors shorting 89bio? 89bio saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 10,120,000 shares, a decrease of 5.9% from the April 30th total of 10,750,000 shares. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is presently 9.6 days. View 89bio's Short Interest. When is 89bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ETNB earnings forecast. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) issued its earnings results on Wednesday, May, 15th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.08. During the same period in the previous year, the firm earned ($0.54) earnings per share. What ETF holds 89bio's stock? AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,900 shares of ETNB stock, representing 0.92% of its portfolio. What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO). When did 89bio IPO? 89bio (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are 89bio's major shareholders? 89bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (12.98%), Janus Henderson Group PLC (12.81%), Vanguard Group Inc. (4.96%), Redmile Group LLC (2.30%), Westfield Capital Management Co. LP (2.27%) and University of Wisconsin Foundation (0.51%). Insiders that own company stock include Edward Morrow Atkinson III, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ETNB) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
